Study identifier:NIS-OCN-ARI-2010/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A prospective, multicenter, non-interventional study to evaluate Quality of Life in Chinese postmenopausal HR(+) EBC patients during adjuvant Aromatase Inhibitors(AIs) treatment
Breast Cancer
-
No
-
Female
494
Observational
50 Years - 70 Years
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Sept 2014 by AstraZeneca
AstraZeneca
-
The purpose of the study is to evaluate quality of life (Qol) in postmenopausal HR (+) EBC patients during adjuvant AIs treatment in terms of: the change of the trial outcome index (TOI) of the FACT-B questionnaire from baseline to 24 months. This study will recruit approximately 500 patients from 21 sites in China. The patients should be postmenopausal HR (+) EBC patients who have already start adjuvant AIs treatment but within 7 days.
Location
Location
Beijing, Beijing, China
Location
Guangzhou, Guangdong, China
Location
Shenzhen, Guangdong, China
Location
Guiyang, Guizhou, China
Location
Harbin, Heilongjiang, China
Location
Changsha, Hunan, China
Location
Nanjing, Jiangsu, China
Location
Changchun, JILIN, China
Arms | Assigned Interventions |
---|---|
1 Chinese postmenopausal HR(+) EBC patients during adjuvant Aromatase Inhibitors(AIs) treatment | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.